MKMeliha Meriç Koç

Meliha Meriç Koç

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Meliha Meriç Koç has a total of 293 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • HIV Testing and Diagnosis Rates in Relation to HIV Indicator Conditions: A Multicenter Retrospective Analysis from Turkey

    by Çiğdem Ataman Hatipoğlu, Serhat Ünal, Meliha Meriç Koç, Figen Kaptan Aydoğmuş, Yaşar Bayındır, Serap Gençer, Yeşim Taşova, Bülent Durdu, Ferit Kuşçu, Bircan Kayaaslan, et al.

    Objective: HIV testing procedure in the presence of HIV indicator conditions is considered an effective strategy to identify undiagnosed people living with HIV. We aimed in this study to evaluate HIV testing and diagnosis rates obtained via non-targeted testing in seven hospitals across Turkey, specifically focusing on patients with HIV indicator conditions. Methods: Data from a total of 3,371,188 patients with hospital admissions for various clinical conditions were analyzed in this retrospective multicenter cross-sectional study, which was carried out in seven hospitals within a 6-months period. HIV testing and HIV diagnosis rates were retrospectively evaluated in the overall population and in the subgroups of patients with and without HIV-indicator conditions. Results: Rates of HIV testing and positivity in the overall population of 3,371,188 patients screened across seven hospitals were 8.3% (281,321/3,371,188) and 0.2% (557/281,321), respectively. HIV testing and HIV positivity rates in 19,410 patients with HIV-indicator conditions were 11.5% (2,225/19,410) and 0.4% (9/2,225), respectively. HIV testing and HIV positivity rates in 3,351,778 patients without HIV-ICs were 8.3% (279,096/3,351,778) and 0.2% (548/279,096), respectively. The rate of HIV testing and HIV positivity in patients with HIV-ICs was statistically significantly higher than in the patients without HIV-ICs (p = 0.000 and p = 0.047, respectively). Discussion: Our findings revealed that only 11.5% of patients with HIV-indicating conditions underwent HIV testing, indicating that most patients are not timely diagnosed despite having HIV-indicating conditions, and these patients remain at risk of living with unknown HIV status. The utilization of testing outside the HIV-indicator conditions criteria in 8.3% of cases was also notable. The likelihood of a positive diagnosis rate was at least 2-fold increased when the screening was guided by HIV-indicator conditions. Conclusion: In conclusion, according to the study, HIV testing in patients with HIV-indicator conditions increased the rate of HIV diagnosis, but the rate of requesting testing in the presence of HIV indicator conditions was low. HIV testing practices among physicians in the Turkish healthcare settings should be improved with interventions for an improved awareness of HIVindicator conditions, guided HIV testing, and adopting the related guidelines to appropriately identify undiagnosed HIV cases.

  • Correction: Diagnosis, Treatment and Prevention of Infective Endocarditis: Turkish Consensus Report

    by Serap Şimşek-Yavuz, Ahmet Rüçhan Akar, Sinan Aydoğdu, Denef Berzeg-Deniz, Hakan Demir, Tuncay Hazırolan, Mehmet Ali Özatik, Necla Özer, Murat Sargın, Emine Nursen Topcuoğlu, et al.

    CORRECTION NOTE A correction has been made to the original version of this article, published as Suppl. 1 in 2019 (Ref: KLM-2890): In Table 25, the information ‘200 mg/day, single dose, oral’ for Doxycycline has been corrected to: ‘200 mg/day, 2 doses, oral’. Corrected article: https://doi.org/10.5152/kd.2019.51


  • Open Access

    Clinical and Epidemiological Evaluation of Adult Measles Cases During a Measles Outbreak

    by Özlem Gökçe, Eda Alp, Gamze Danacı, Alper Gündüz, Özlem Altuntaş-Aydın, Meliha Meriç Koç, Nuran Karabulut, Sema Alaçam, Selda Kömeç

    Objective: Measles is a highly contagious, vaccine-preventable disease caused by the measles virus. There has been a marked increase in measles cases in Türkiye in recent years. This study aimed to evaluate the clinical and epidemiological characteristics of adult measles cases at our hospital between 2022 and 2023. Methods: This retrospective, cross-sectional study included patients 18 years and older diagnosed with measles between January 2022 and September 2023. Diagnosis was confirmed by measles immunoglobulin M (IgM) or polymerase chain reaction (PCR) testing. Researchers reviewed sociodemographic data, clinical signs and symptoms, and laboratory parameters including complete blood count (CBC), aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), and C-reactive protein (CRP), as well as chest radiographs. Data were extracted from the hospital information system. Descriptive statistics (mean, standard deviation, and percentage) were used. Categorical variables were summarized as frequency (n) and percentage (%). Results: A total of 162 adult measles cases were included. The first two cases appeared in 2022. The rest occurred in 2023. The number of cases peaked in May 2023 and declined afterward. Of the cases, 98 (60%) were female. Of these, 5 (5%) were pregnant. The median age was 27 years (range: 18–51). Twelve cases (0.7%) were foreign nationals. Only 17 patients (10.5%) had a history of full-dose measles vaccination. The most common symptoms were rash (100%), fever (81%), and cough (65%). Measles IgM was positive in 126 patients (78%). All 36 IgM-negative patients tested positive by PCR. Laboratory findings showed elevated aminotransferases in 86 patients (53%), leukopenia in 30 (18.5%), and thrombocytopenia in 46 (28%). Thirteen patients (0.8%) required hospitalization. All recovered with supportive care, and no deaths occurred. Conclusion: The sharp increase in measles cases shows a decline in herd immunity. Preventive measures are urgently needed. Measles should be considered in the differential diagnosis of patients with rash and fever and serological and PCR testing should be used. Public health authorities should be notified promptly and isolation precautions should be implemented to prevent outbreaks.

  • Clinical significance of non-infectious procalcitonin elevation in Still’s disease: a predictor of macrophage activation syndrome

    by Erdem Bektas, Burcu Ceren Uludogan, Busra Firlatan Yazgan, Ozgur Can Kilinc, Beste Acar, Oguzhan Kizilkaya, Aysenur Yilmaz, Busra Yuce, Reside Borce Aydin, Meliha Meric Koc, et al.

    Objectives: Still’s disease (SD) is an autoinflammatory disease (AID) that can lead to life-threatening macrophage activation syndrome (MAS). The role of procalcitonin (PCT) in AIDs remains unclear. This study aims to explore the relationship between non-infectious PCT elevation and clinical features of SD. Methods: This retrospective study included patients with SD and absence of infection who had available PCT data. Control groups consisted of patients with confirmed bloodstream infections and age- and sex-matched healthy controls (HCs). A PCT cut-off of 0.5 ng/ml was used. Clinical and laboratory findings were evaluated based on baseline (PCT < 0.5 and PCT ≥ 0.5 groups) and maximum (PCTmax < 0.5 and PCTmax ≥ 0.5 groups) values. Results: The study conducted with 110 patients with SD. Of these, 75 (68%) were in the PCT < 0.5 group and 35 (32%) were in the PCT ≥ 0.5 group, while 63 (57.3%) were in the PCTmax < 0.5 group and 47 (42.7%) were in the PCTmax ≥ 0.5 group. PCT levels were significantly higher in patients with SD compared with HCs and were nearly as elevated in MAS cases as in infection. Frequency of MAS, higher mPouchot scores and increased use of biologic DMARDs, particularly anakinra, were associated with elevated PCT. MAS risk increased 6.4-fold in the PCT ≥ 0.5 group and 7.6-fold in the PCTmax ≥ 0.5 group in univariate analysis, and 4.3-fold and 5.4-fold, respectively, in multivariate analysis. Conclusion: PCT may be a potential marker in AIDs such as SD, even in the absence of infection. Elevated PCT levels may serve as an independent predictor of MAS in SD.


  • Open Access

    Emerging West Nile virus infections in Türkiye

    by Özlem Alhan, Meliha Meriç Koç, Ayşe Batırel, Emel Yılmaz, Gülden Ersöz, Mehtap Aydın, Merve Üstüner Doğan, Hande Hazır Konya, Üner Kayabaş, Ferit Kuşçu, et al.

    Purpose: Türkiye experienced its largest West Nile virus (WNV) infection outbreak in 2024. We described the clinical and laboratory features of human cases with WNV infection collected from eleven tertiary hospitals in Türkiye in 2024. Methods: The clinical characteristics of the patients were gathered using a structured form in the retrospective study. According to the ECDC case definition of WNV infections, the patients were classified as ‘confirmed’ or ‘probable’ cases. The odds ratio (OR) and 95% confidence interval (CI) for possible mortality predictors in WNV infections were calculated using multivariate logistic regression analysis. p < 0.05 was considered statistically significant. Results: The mean age of the 51 patients was 63.3 ± 13.6 years, and 37 (72.5%) were male. Twenty-six cases (51%) were confirmed, and 49% were probable WNV infection. Forty-eight patients (94.1%) had WNV neuroinvasive disease: 24 (47%) were diagnosed with meningoencephalitis, 20 (39.2%) with encephalitis, one (2%) with meningitis, and seven (13.7%) with acute flaccid paralysis. Twenty patients (39.2%) had movement disorders (tremor, myoclonus, bradykinesia, or rigidity). The case fatality rate was 17.6%. In multivariate analysis, older age (OR: 1.09, CI: 1.03–1.19, p = 0.042) and secondary bacterial infection during hospitalization (OR: 10, CI: 1.55–64.95, p = 0.015) were associated with fatality. Conclusion: We highlighted the increasing number of cases and diagnostic challenges by describing the highest number of the patients with WNV infections in Türkiye. Raising awareness among healthcare professionals, facilitating access to diagnostic tests, and developing rapid, reliable, and easily applicable tests would enable early diagnosis and help improve outcomes.


  • Open Access

    Correction to: Investigation of Factors Affecting IgG Antibody Response in COVID-19 Cases

    by Ayse Betul Uslu-Ersoz, Meliha Meric Koc, Sibel Bolukcu, Bilge Sumbul

    CORRECTION NOTE The original version of this article, unfortunately, contained a mistake. 4h author name (Bilge Sümbül) is missing in the published version. The original article has been corrected. Corrected article: https://doi.org/10.36519/kd.2024.4781

  • Open Access

    Investigation of Factors Affecting IgG Antibody Response in COVID-19 Cases

    by Ayse Betul Uslu-Ersoz, Meliha Meric Koc, Sibel Bolukcu

    Objective: His study aimed to evaluate the factors influencing antibody titers and duration of antibody positivity against SARS-CoV-2 in COVID-19 patients followed for a year. Methods: Adult patients diagnosed with COVID-19 between March and August 2020 were included. Patient data, including age, gender, body mass index (BMI), Charlson comorbidity index (CCI), and clinical severity scores, were recorded. Patients were evaluated four times, and quantitative antibody titers were measured. Results: 53.1% of 177 patients were male, with a median age of 47 (IQR=33.5-55). 39.5% had additional comorbidities. Based on clinical severity, 33.3% were mild, 46.9% were moderate, and 19.8% were severe cases. The median intervals at visits were 56. 92, 193, and 371 days. Antibody positivity rates decreased, with 88.7%, 80.8%, 45.9%, and 21.4% at each visit. Median SARS-CoV-2 anti-N IgG titers decreased, particularly at the third visit (p<0.0001). Significant correlations were found between anti-N IgG titers and disease severity. Multivariate analysis showed that as disease severity increased, the probability of antibody positivity at the first and third visits increased approximately 3 to 6 times. Age and CCI score were also independent variables affecting antibody positivity. Conclusion: We observed a significant decrease in anti-N IgG antibody titers, especially after six months, and a considerable decline within one year. Disease severity was the most significant factor affecting antibody positivity, followed by age and CCI score. The study suggests further research to understand the duration of SARS-CoV-2-induced antibodies, seropositivity, and protective immunity.

  • Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers in People Living with HIV/AIDS in Türkiye

    by Erkan Yılmaz, Ahmet Furkan Kurt, Mehtap Dogruel, Dilek Yıldız Sevgi, Hayat Kumbasar Karaosmanoglu, Esra Zerdali, Meliha Meric Koc, Bilgul Mete, Fehmi Tabak

    Introduction: Abacavir is among the first-line initial antiretroviral regimens for most patients living with HIV/AIDS (PLWHA). Although well tolerated, it is associated with hypersensitivity reaction (HSR), which is treatment-limiting and potentially life-threatening. HSR was shown to be associated with the class I MHC allele, HLA-B*57:01. In this study, we aimed to evaluate the prevalence of HLA-B*57:01 in PLWHA in Istanbul, Türkiye. Material and Methods: Five HIV treatment centers in Istanbul included all sequential treatment-- naïve, ≥ 18 years adult PLWHA, between December 2017- December 2021. Demographic, clinical, and laboratory data were collected at baseline and during treatment. HLA-B* 57:01 genotyping was determined with PCR-SSP. Results: Eight hundred sixty-seven PLWHA were included (male:91%, mean age 39.6±11.1 years). 1.6% of patients were found to be HLA-B*57:01 positive. Among HLA-B*57:01 positive patients, 4 were initially given abacavir-containing treatment; they were switched to non-abacavir treatment upon the allele found to be positive. Conclusion: Although previous studies reported the HLA-B*57:01 prevalence of PLWHA in Türkiye as 3-3.6%, we have found the prevalence to be 1.6%. The current study includes higher numbers of patients than the previous studies. Furthermore, patients from all over the country apply to the centers in Istanbul; compared to the other studies, which involve patients limited to the relevant regions, it can be assumed that the number in our cohort is more representative of the country. In conclusion, the prevalence of the HLA-B*57:01 allele in PLWHA in this study is relatively low. With evident benefit in preventing abacavir HSR, HLA-B*57:01 should be screened in planning antiretroviral therapy.


  • Open Access

    Results of Nucleos(t)ide Analog Treatment Discontinuation in Hepatitis B e-Antigen-Negative Chronic Hepatitis B: NUCSTOP Study

    by Sercan Kiremitçi, Koray Koçhan, Gülseren Seven, Elmas Biberci Keskin, Gülay Okay, Yasemin Akkoyunlu, Meliha Meriç Koç, Bilge Sümbül, Hakan Şentürk

    Background/Aims: This study aims to investigate the effects of nucleos(t)ide analogs (NAs) discontinuation in eligible patients in accor dance with the Asian Pacific Association for the Study of the Liver hepatitis B guideline and the factors affecting clinical and virological relapses. Materials and Methods: In this prospectively designed study, hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients who were followed up between 2012 and 2019 were evaluated and 57 patients were included. All participants enrolled the study were HBeAg negative status at NA initiation. Results: The median age of the patients was 49 (29-72) years and 24 (42%) were females. The median treatment duration was 96 (36 276) months and patients were followed for a median duration of 27 months. Sixteen patients had a previous history of NA switch, and thirteen of these patients had a history of lamivudine resistance. Thirty-eight of 57 patients (66%) developed an elevated hepatitis B virus deoxyribonucleic acid level of >2000 IU/mL at least once, defined as virological relapse and 23 (60%) of them, experienced clinical relapse. Thirty-one of 57 patients were re-treated during the follow-up, and hepatitis B surface antigen (HBsAg) loss occurred among 4 (7%) patients. All patients who experienced HBsAg loss had a history of lamivudine resistance (P = .002). Conclusion: Despite receiving NAs suppression therapy for a long time, HBsAg loss occurs rarely. Although it was not life-threatening, most patients experienced relapses and treatment should be restarted. In our study, whether it is a coincidence that all patients with HBsAg loss are patients in whom NAs are used sequentially due to lamivudine resistance is an issue that needs to be further investigated. Cite this article as: Kiremitçi S, Koçhan K, Seven G, et al. Results of nucleos(t)ide analog treatment discontinuation in hepatitis B e-antigen-negative chronic hepatitis B: NUCSTOP study. Turk J Gastroenterol. 2024;35(1):17-26.